60Q Stock Overview
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Captor Therapeutics Spolka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł10.20 |
| 52 Week High | zł23.90 |
| 52 Week Low | zł9.76 |
| Beta | 0.58 |
| 11 Month Change | -33.98% |
| 3 Month Change | -40.35% |
| 1 Year Change | -47.01% |
| 33 Year Change | -73.57% |
| 5 Year Change | n/a |
| Change since IPO | -72.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 60Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.9% | -1.1% | 1.1% |
| 1Y | -47.0% | -18.8% | 7.2% |
Return vs Industry: 60Q underperformed the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: 60Q underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 60Q volatility | |
|---|---|
| 60Q Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 60Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 60Q's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 105 | Tom Shepherd | www.captortherapeutics.com |
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage.
Captor Therapeutics Spolka Akcyjna Fundamentals Summary
| 60Q fundamental statistics | |
|---|---|
| Market cap | €51.85m |
| Earnings (TTM) | -€9.55m |
| Revenue (TTM) | €4.49m |
11.5x
P/S Ratio-5.4x
P/E RatioIs 60Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 60Q income statement (TTM) | |
|---|---|
| Revenue | zł19.36m |
| Cost of Revenue | zł8.32m |
| Gross Profit | zł11.04m |
| Other Expenses | zł52.19m |
| Earnings | -zł41.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.83 |
| Gross Margin | 57.02% |
| Net Profit Margin | -212.61% |
| Debt/Equity Ratio | 0% |
How did 60Q perform over the long term?
See historical performance and comparison